The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients

Journal of Clinical Immunology

Volumn 24, Issue 2, 2004, Pages 170-176

  Fernvik, Eva C ^a   Ketelhuth, Daniel F J ^a   Russo, Momtchilo ^a   Gidlund, Magnus ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b IMTSP   (Brazil)

Author keywords

Antibodies; Atherosclerosis and macrophages; oxLDL

Indexed keywords

AUTOANTIBODY; COPPER ION; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ANIMAL CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 1842555494     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:JOCI.0000019782.67993.0b     Document Type: Article

References (33)

1. Ross R, Glomset JA: The paihogenesis of atherosclerosis. N Eng J Med 295:369-377, 1976
2. Ross R: Atherosclerosis - An inflammatory disease. N Engl J Med 340:115-126, 1999
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
4. Esterbauer H, Gebicki J, Puhl H, Jurgens G: The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13:341-390, 1992
5. Frostegard J, Haegerstrand A, Gidlund M, Nilsson J: Biologically modified LDL increases the adhesive properties of endothelial cells. Atherosclerosis 90:119-126, 1991
6. Libby P: Changing concepts of atherogenesis. J Intern Med 241:349-358, 2000
7. Folcik VA, Aamir R, Cathcart MK: Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler Thromb Vasc Biol 17:1954-1961, 1997
8. Jonasson L, Holm J, Skalli O, Bondjers G, and Hansson GK: Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 6:131-138, 1986
9. Ross R: The patogenesis of atherosclerosis: A perspective for the 1990s. Nature 362:801-809, 1993
10. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci USA 92:3893-3897, 1995
11. Zhou X, Hansson GK: Detection of B cells and proinflammatory cytokines in atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. Scand J Immunol 50:25-30, 1999
12. Shoenfeld Y, Sherer Y, George J, Harats D: Autoantibodies associated with atherosclerosis. Ann Med 32(Suppl 1):37-40, 2000
13. Palinski W, Yla-Herttuala S, Rosenfeld ME, Butler SW, Socher SA, Parthasarathy S, Curtiss LK, Witztum JL: Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 10:325-335, 1990
14. Bui MN, Sack MN, Moutsatsos G, Lu DY, Katz P, McCown R, Breall JA, Rackley CE: Autoantibody titers to oxidized low-density lipoprotein in patients with coronary atherosclerosis. Am Heart J 131:663-667, 1996
15. Puurunen M, Manttari M, Manninen V, Tenkanen L, Alfthan G, Ehnholm C, Vaarala O, Aho K, Palosuo T: Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 154:2605-2609, 1994
16. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G: Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: A biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens 13:129-138, 1995
17. Bergmark C, Wu R, de Faire U, Lefvert AK, Swedenborg J: Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 15:441-445, 1995
18. Zaratin A, Gidlund M, Boschcov P, Castilho L, Cotta de Faria E: Antibodies against oxidized low-density lipoprotein in normolipidemic smokers. Am J Cardiol 90:651, 2002
19. Shoji T, Nishizawa Y, Fukumoto M, Shimamura K, Kimura J, Kanda H, Emoto M, Kawagishi T, Morii H: Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 148:171-177, 2000
20. Uusitupa MI, Niskanen L, Luoma J, Vilja P, Mercuri M, Rauramaa R, Yla-Herttuala S: Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. ArteriosclerThromb Vasc Biol 16:1236-1242, 1996
21. Hulthe J, Wikstrand J, Lidell A, Wendelhag I, Hansson GK, Wiklund O: Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 18:1203-1211, 1998
22. van de Vijver LP, Steyger R, van Poppel G, Boer JM, Kruijssen DA, Seidell JC, Princen HM: Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 122:245-253, 1996
23. Sherer Y, Shoenfeld Y: Immunomodulation for treatment and prevention of atherosclerosis. Autoimmunity Rev 1:21-27, 2002
24. Damasceno NR, Goto H, Rodrigues FM, Dias CT, Okawabata FS, Abdalla DS, Gidlund M: Soy protein isolate reduces the oxidizability of LDL and the generation of oxidized LDL autoantibodies in rabbits with diet-induced atherosclerosis. J Nutr 130:2641-2647, 2000
25. Uint L, Gebara OCE, Pinto LB, Boschcov P, Luz PL, Gildund M: Hormone replacement therapy (HRT) increases antibodies against heat shock protein 65 (Hsp 65) and oxidized LDL (oxLDL). Brazil J Med Biolog Res 36:491-494, 2003
26. Havel RJ, Eeder HA, Gragdon JH: [The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum]. J Clin Invest 34:345-353, 1955
27. Lowry OH, Rosebbough NJ, Farr AL, Randall RJ: Protein measurement with the folin phenol reagent. J Biol Chem. 193:265-275, 1951
28. Svensjo E, Boschcov P, Ketelhuth DFJ, Jancar S, Gidlund M: Increased microvascular permeability in the hamster cheek pouch induced by oxidized low density lipoprotein (oxLDL) and some fragmented apolipoprotein B proteins. Inflamm Res 52:215-220, 2003
29. Puhl H, Waeg G, Esterbauer H: Methods to determine oxidation of low-density lipoproteins. Methods Enzymol 233:425-441, 1994
30. Carvalho MD, Harada LM, Gidlund M, Ketelhuth DF, Boschcov P, Quintao EC: Macrophages take up triacylglycerol-rich emulsions at a faster rate upon co-incubation with native and modified LDL: An investigation on the role of natural chylomicrons in atherosclerosis. J Cell Biochem 84:309-323, 2002
31. Ketelhuth DFJB P, Carvalho MDT, Gidlund M: Separation of low-density lipoprotein (LDL) and oxidised LDL (oxLDL) sub-species and reactivity against autoantibodies. Revista da Sociedade Brasileira de Medicina Tropical 34, 2001 (Abstract)
32. Brown MS, Goldstein JL: Lipoprotein metabolism in the macrophage: Implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem 52:223-261, 1983
33. Hamilton TA, Major JA, Armstrong D, Tebo JM: Oxidized LDL modulates activation of NFkappaB in mononuclear phagocytes by altering the degradation if IkappaBs. J Leukoc Biol 64:667-674, 1998